SourceBio International plc
(“SourceBio, the “Company” or the “Group”)  

Investor Presentation 


SourceBio International plc (AIM: SBI), leading international provider of integrated state-of-the-art laboratory services and products, announces that it will be hosting a live online presentation open to all investors on Thursday 12 November at 4.30pm, delivered by Jay LeCoque, Executive Chairman, Tony Ratcliffe, CFO and Russell Wheatcroft, COO.  


The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on its recent admission to AIM and provide an overview of the Company and its four main areas of focus, including the significant Covid-19 testing opportunity.  


The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet SourceBio International plc via the following link: 


For those investors who have already registered and added to meet the Company, they will automatically be invited.  


Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the “Ask a Question” function.  Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. 





SourceBio International plc                    

Jay LeCoque, Executive Chairman 

Via Walbrook PR 

Tony Ratcliffe, Chief Financial Officer   
Walbrook PR Limited 

Tel: 020 7933 8780 or 

Paul McManus 

Mob: 07980 541 893 

Sam Allen 

Mob: 07748 651 727 


About SourceBio International plc ( 


SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products clients in the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis, management and care. Group revenues are derived from four core businesses areas: 


  • Healthcare Diagnostics – histopathology and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland; 
  • Genomics – DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in the UK, Europe and North America; 
  • Stability Storage – shelf life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies from around the world but primarily in the UK, Ireland and the USA; and 
  • Infectious Disease Testing – since May 2020, the Group has provided COVID-19 Antigen RT-PCR testing services. These services passed all of the auditing requirements of the NHS and the Department of Health and Social Care (DHSC) in April 2020. It is intended that this offering will potentially provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future. 


More details on Group operations can be found